United Capital Financial Advisors LLC Takes Position in Kenvue Inc. $KVUE

Posted by Stanley Muller on Aug 31st, 2026

United Capital Financial Advisors LLC bought a new stake in Kenvue Inc. (NYSE:KVUE – Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 48,364 shares of the company’s stock, valued at approximately $924,000.

Several other institutional investors and hedge funds have also bought and sold shares of KVUE. Jefferies Financial Group Inc. bought a new position in Kenvue in the second quarter valued at approximately $26,755,000. Public Employees Retirement System of Ohio bought a new stake in shares of Kenvue during the 2nd quarter worth approximately $10,328,000. One68 Global Capital LLC bought a new stake in shares of Kenvue during the 2nd quarter worth approximately $283,000. Stonehage Fleming Financial Services Holdings Ltd acquired a new stake in shares of Kenvue in the 2nd quarter valued at approximately $82,000. Finally, Transamerica Financial Advisors LLC acquired a new stake in shares of Kenvue in the 2nd quarter valued at approximately $272,000. Institutional investors own 97.64% of the company’s stock.

Kenvue Stock Performance

Shares of NYSE KVUE opened at $19.15 on Monday. The company has a current ratio of 1.01, a quick ratio of 0.71 and a debt-to-equity ratio of 0.67. The company has a market capitalization of $36.78 billion, a P/E ratio of 22.01, a P/E/G ratio of 1.37 and a beta of 0.47. Kenvue Inc. has a 12 month low of $14.02 and a 12 month high of $20.82. The stock has a 50 day moving average of $19.16 and a 200-day moving average of $18.25.

Kenvue (NYSE:KVUE – Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.31 earnings per share for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). Kenvue had a net margin of 10.76% and a return on equity of 21.22%. The business had revenue of $3.96 billion during the quarter, compared to the consensus estimate of $3.97 billion. During the same quarter last year, the company posted $0.29 EPS. The firm’s revenue was up 3.0% on a year-over-year basis. As a group, equities research analysts predict that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, August 26th. Shareholders of record on Wednesday, August 12th were issued a $0.21 dividend. This is an increase from Kenvue’s previous quarterly dividend of $0.21. This represents a $0.84 annualized dividend and a dividend yield of 4.4%. The ex-dividend date was Wednesday, August 12th. Kenvue’s dividend payout ratio is presently 96.55%.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. UBS Group lowered their target price on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a report on Tuesday, August 11th. Barclays increased their price target on shares of Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 21st. Wall Street Zen downgraded shares of Kenvue from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Weiss Ratings upgraded shares of Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, June 15th. Finally, Zacks Research cut shares of Kenvue from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. Three analysts have rated the stock with a Buy rating and twelve have issued a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $19.27.

Get Our Latest Research Report on KVUE

Kenvue Company Profile

(Free Report)

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.